Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaOla Landgren, Neha Korde, Kelly Werner et al.|JAMA Oncology|2021Cited by 119
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaOla Landgren, Ingemar Turesson, Jonathan N. Hofmann et al.|JAMA Oncology|2019Cited by 97
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Ola Landgren, Neha Korde et al.|The Lancet Haematology|2021Cited by 95
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignanciesRobert Stuver, Santosha A. Vardhana, Gunjan L. Shah et al.|Cancer Cell|2022Cited by 88
Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapiesA. Shamseddine, Adam M. Schmitt, Suchit H. Patel et al.|The Journal of Experimental Medicine|2022Cited by 26